Jaguar Health Stock Price, News & Analysis (NASDAQ:JAGX)

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

Jaguar Health Inc (NASDAQ:JAGX) released its quarterly earnings data on Wednesday, August, 14th. The biotechnology company reported ($9.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by $3.48. The biotechnology company earned $1.71 million during the quarter, compared to analysts' expectations of $3.05 million. Jaguar Health had a negative net margin of 727.27% and a negative return on equity of 698.61%. View Jaguar Health's Earnings History.

Jaguar Health is scheduled to release their next quarterly earnings announcement on Monday, November 18th 2019. View Earnings Estimates for Jaguar Health.

2 brokerages have issued 12-month price objectives for Jaguar Health's shares. Their predictions range from $5.00 to $10.00. On average, they anticipate Jaguar Health's stock price to reach $7.50 in the next year. This suggests a possible upside of 849.4% from the stock's current price. View Analyst Price Targets for Jaguar Health.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Jaguar Health.

Media headlines about JAGX stock have trended somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Jaguar Health earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Jaguar Health.

Jaguar Health saw a drop in short interest in September. As of September 15th, there was short interest totalling 107,700 shares, a drop of 26.4% from the August 15th total of 146,400 shares. Based on an average daily trading volume, of 994,700 shares, the days-to-cover ratio is presently 0.1 days. Currently, 5.9% of the company's shares are short sold. View Jaguar Health's Current Options Chain.

Some companies that are related to Jaguar Health include Northwest Biotherapeutics (NWBO), Avadel Pharmaceuticals (AVDL), Harrow Health (HROW), American Brivision (Holding) (ABVC), MEI Pharma (MEIP), Generex Biotechnology (GNBT), Mustang Bio (MBIO), Sesen Bio (SESN), CytoDyn (CYDY), Axovant Gene Therapies (AXGT), Kala Pharmaceuticals (KALA), PhaseBio Pharmaceuticals (PHAS), Scpharmaceuticals (SCPH), IDEAYA Biosciences (IDYA) and Paratek Pharmaceuticals (PRTK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Conatus Pharmaceuticals (CNAT), Biopharmx (BPMX), Cara Therapeutics (CARA), Cascadian Therapeutics (CASC), PTC Therapeutics (PTCT), Neovasc (NVCN), Precipio (PRPO), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN) and Viking Therapeutics (VKTX).

(JAGX) raised $22 million in an initial public offering on Wednesday, May 13th 2015. The company issued 3,200,000 shares at $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

Jaguar Health's stock is owned by a number of of institutional and retail investors. Top institutional investors include Wedbush Securities Inc. (0.05%). Company insiders that own Jaguar Health stock include James J Bochnowski, Jonathan B Siegel, Lisa A Conte and Nantucket Investments Ltd. View Institutional Ownership Trends for Jaguar Health.

JAGX stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Jaguar Health stock in the last two years include James J Bochnowski, Jonathan B Siegel and Lisa A Conte. View Insider Buying and Selling for Jaguar Health.

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of JAGX stock can currently be purchased for approximately $0.79.

Jaguar Health has a market capitalization of $36.62 million and generates $4.42 million in revenue each year. The biotechnology company earns $-32,150,000.00 in net income (profit) each year or ($158.74) on an earnings per share basis. Jaguar Health employs 40 workers across the globe.View Additional Information About Jaguar Health.

The official website for Jaguar Health is http://www.jaguaranimalhealth.com/.

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.